Expert thinking on productivity, intangible asset valuation, growth strategy, and building more valuable businesses.
Healthcare and MedTech companies invest billions in clinical evidence, regulatory approvals, and proprietary health data — assets that represent formidable barriers to competition and durable sources of revenue. Yet these assets remain largely invisible to the lending market. Here is how structured intangible collateral can transform healthcare financing.
Read more →
IAS 38 hasn't kept pace with the intangible economy. See what IASB, CSRD and FRC updates mean for SMEs preparing for exit or investor reporting in 2026.
Read more →
Revenue-based financing offers startups non-dilutive capital tied to revenue performance. Equity financing offers larger sums but permanent dilution. The right choice depends on which intangible assets you are building — and whether those assets benefit more from capital preservation or capital scale.
Read more →
How to value in-process research and development (IPR&D) in purchase price allocations under IFRS 3 and ASC 805. Covers probability-adjusted cash flow modelling, completion risk assessment, and the critical accounting differences between standards.
Read more →
How to value an assembled workforce using the cost approach. Covers replacement cost components, the role of assembled workforce in MPEEM contributory charges, and why this asset is not separately recognised under IFRS 3 despite being essential to every PPA.
Read more →
Every startup generates intellectual property from its earliest days. The question is whether that IP is identified, protected, and valued as the strategic asset it is — or whether it leaks away through poor contracts, inadequate protection, and a failure to recognise what has been created.
Read more →
Every AI deployment depends on foundation models, cloud providers, and data sources. Here is how to audit your AI supply chain before risks surface.
Read more →
A comprehensive explanation of contributory asset charges (CACs) in the Multi-Period Excess Earnings Method. Covers the economic rationale, calculation methods for each asset type, and common errors that distort intangible asset valuations.
Read more →
Stock options are the primary tool startups use to attract and retain talent. But the value of those options depends on the intangible assets the company is building. When you understand this connection, you design option schemes that align incentives with the real drivers of company value.
Read more →
FinTech companies combine technology IP, proprietary data, regulatory licences, and customer networks into asset bases of extraordinary value — yet they remain among the most difficult to finance through traditional lending. The structured finance techniques that can unlock this collateral draw directly on the principles of asset-backed securities that have served traditional finance for decades.
Read more →
How PE firms and portfolio companies use the Opagio growth platform to identify, measure, and position intangible assets ahead of exit — turning invisible value into higher multiples and faster deal completion.
Read more →
In November 2021, some of the world's leading researchers on intangible assets gathered at RSA House in London. Opagio's Chief Scientist David Stroll presented his paper on collecting firm-level intangible asset data.
Read more →Get the latest insights on intangible asset growth and productivity delivered to your inbox.
Get a free productivity assessment and discover where your biggest growth opportunities lie.